Effect of silibinin on liver aminotransferases in patients with nonalcoholic fatty liver disease: A meta-analysis
10.3969/j.issn.1001-5256.2019.05.024
- VernacularTitle:水飞蓟宾治疗对非酒精性脂肪性肝病患者转氨酶影响的Meta分析
- Author:
Yue CHANG
1
;
Wen ZHANG
;
Qinyu LIU
Author Information
1. Department of Hepatopancreatobiliary and Splenic Medicine, Affiliated Hospital of Logistics University of Chinese People′s Armed Police Forces, Tianjin 300162, China
- Publication Type:Research Article
- Keywords:
non-alcoholic fatty liver disease;
silibinin;
transaminases;
Meta-analysis
- From:
Journal of Clinical Hepatology
2019;35(5):1057-1060
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo conduct a meta-analysis of the articles on the effect of silibinin on aminotransferases in patients with nonalcoholic fatty liver disease (NAFLD), and to investigate the liver-protecting effect of silibinin in patients with NAFLD. MethodsCNKI, Wanfang Data, VIP, SinoMed, PubMed, MEDLINE, Embase, and ScienceDirect were searched for randomized controlled trials (RCTs) on the treatment of NAFLD patients with silibinin, The articles were screened according to inclusion and exclusion criteria, and then quality assessment and data extraction were performed. RevMan 5.3 was used to perform the meta-analysis. ResultsA total of 8 articles with 665 patients were included. After 8 weeks to 3 months of silibinin treatment, there were significant reductions in the serum levels of alanine aminotransferase (ALT) (weighted mean difference ［WMD］=-11.60, 95% confidence interval ［CI］: -18.68 to -4.51, P=0.001) and aspartate aminotransferase (AST) (WMD=-11.56, 95% CI: -16.93 to -6.18, P＜0.001). Conclusion Silibinin can significantly reduce the serum levels of ALT and AST in patients with NAFLD.
